Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Fludarabine
Drug ID BADD_D00914
Description Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.
Indications and Usage For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen
Marketing Status approved
ATC Code L01BB05
DrugBank ID DB01073
KEGG ID D07966
MeSH ID C024352
PubChem ID 657237
TTD Drug ID D0F2XQ
NDC Product Code 16729-131
UNII P2K93U8740
Synonyms fludarabine | 9H-purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro- | F-ara-A | 2-fluoroadenine arabinoside | 9-beta-D-arabinofuranosyl-2-fluoroadenine
Chemical Information
Molecular Formula C10H12FN5O4
CAS Registry Number 21679-14-1
SMILES C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)O)F)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Haemorrhage24.07.01.0020.000280%Not Available
Skin toxicity12.03.01.020; 23.03.03.032--Not Available
Drug resistance08.06.01.0050.000112%Not Available
Cardiac disorder02.11.01.0030.000448%Not Available
Haematotoxicity12.03.01.025; 01.05.01.0070.000168%Not Available
Lymphoproliferative disorder01.13.02.001; 16.21.02.001--Not Available
Mucosal haemorrhage24.07.01.011; 08.01.06.0050.000112%Not Available
Optic nerve disorder17.04.05.004; 06.02.08.001--
Decreased appetite14.03.01.005; 08.01.09.028--
Renal function test abnormal13.13.01.012--Not Available
Ill-defined disorder08.01.03.049--Not Available
Autoimmune disorder10.04.04.003--
Bone marrow disorder01.05.01.0060.000112%Not Available
Disease progression08.01.03.0380.000616%
Non-small cell lung cancer16.19.01.001; 22.08.01.0020.000112%Not Available
Pulmonary toxicity22.01.02.007; 12.03.01.013--Not Available
Hepatobiliary disease09.01.08.003--Not Available
Venoocclusive disease24.03.02.0160.001231%Not Available
Bone marrow failure01.03.03.0050.001063%
Acute graft versus host disease12.02.09.002; 10.02.01.0280.001399%Not Available
Chronic graft versus host disease12.02.09.003; 10.02.01.0290.000280%Not Available
Cytopenia01.03.03.0120.000168%Not Available
Haematological malignancy16.21.01.002; 01.13.01.0030.001007%Not Available
Brain injury19.07.03.007; 17.11.01.0030.000168%Not Available
X-linked lymphoproliferative syndrome03.17.01.002; 01.13.02.003; 16.21.02.003; 11.05.10.005; 10.03.01.003--Not Available
Acute kidney injury20.01.03.0160.000895%
Posterior reversible encephalopathy syndrome17.13.02.0070.001063%
Autoimmune haemolytic anaemia10.04.01.005; 01.06.01.0040.000112%Not Available
Multiple organ dysfunction syndrome08.01.03.0570.000839%
B precursor type acute leukaemia01.10.01.004; 16.01.01.0040.000112%Not Available
The 8th Page    First    Pre   8 9    Next   Last    Total 9 Pages